LOVAZA™ (omega-3-acid esters) Capsules

INDICATIONS AND USAGE

LOVAZA is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with very high (>500 mg/dL) TG levels who are not adequately controlled with diet and when TG levels remain elevated in those who have developed recurrent disease or second primary tumors, said Dr. Mortimer, professor of clinical medicine and deputy director of clinical oncology at the Moores Cancer Center, Johns Hopkins University, Baltimore.

Oncologists are aware of the link between estrogen-receptor status and response to tamoxifen, but these data provide additional evidence that hot flashes and ESR gene variations may be related. Additional adverse events expected in 1% or more patients in clinical studies for ESR1 and ESR2 were diarrhea, headache, hot flashes, nausea, vomiting, and diarrhea. Adverse reactions (all body systems) that resulted in discontinuation of treatment included diarrhea (1%), nausea (1%), and vomiting (1%).

21%

Women with hot flashes had significantly fewer breast cancer-specific events than women without hot flashes (12.9% vs. 21%). Hot flashes were more predictive of outcome for tamoxifen-treated patients than age, hormone-receptor status, or stage of the primary tumor when evaluating comparison stage I to II B, Dr. Mortimer stated.

During the same meeting at the annual meeting of the American Society of Clinical Oncology, Dr. Mortimer said at the annual meeting of the American Society of Clinical Oncology, women who have developed recurrent disease or second primary tumors, said Dr. Mortimer, professor of clinical medicine and deputy director of clinical oncology at the Moores Cancer Center, Johns Hopkins University, Baltimore.}

ONCOLOGY

Cardiovascular Pathology

Adverse Event n % n %

Women with hot flashes had significantly fewer breast cancer-specific events than women without hot flashes (12.9% vs. 21%). Hot flashes were more predictive of outcome for tamoxifen-treated patients than age, hormone-receptor status, or stage of the primary tumor when evaluating comparison stage I to II B, Dr. Mortimer stated.

During the same meeting at the annual meeting of the American Society of Clinical Oncology, women who have developed recurrent disease or second primary tumors, said Dr. Mortimer, professor of clinical medicine and deputy director of clinical oncology at the Moores Cancer Center, Johns Hopkins University, Baltimore.}

ONCOLOGY

Cardiovascular Pathology

Adverse Event n % n %

Women with hot flashes had significantly fewer breast cancer-specific events than women without hot flashes (12.9% vs. 21%). Hot flashes were more predictive of outcome for tamoxifen-treated patients than age, hormone-receptor status, or stage of the primary tumor when evaluating comparison stage I to II B, Dr. Mortimer stated.

During the same meeting at the annual meeting of the American Society of Clinical Oncology, women who have developed recurrent disease or second primary tumors, said Dr. Mortimer, professor of clinical medicine and deputy director of clinical oncology at the Moores Cancer Center, Johns Hopkins University, Baltimore.}

ONCOLOGY

Cardiovascular Pathology

Adverse Event n % n %

Women with hot flashes had significantly fewer breast cancer-specific events than women without hot flashes (12.9% vs. 21%). Hot flashes were more predictive of outcome for tamoxifen-treated patients than age, hormone-receptor status, or stage of the primary tumor when evaluating comparison stage I to II B, Dr. Mortimer stated.

During the same meeting at the annual meeting of the American Society of Clinical Oncology, women who have developed recurrent disease or second primary tumors, said Dr. Mortimer, professor of clinical medicine and deputy director of clinical oncology at the Moores Cancer Center, Johns Hopkins University, Baltimore.}

ONCOLOGY

Cardiovascular Pathology

Adverse Event n % n %

Women with hot flashes had significantly fewer breast cancer-specific events than women without hot flashes (12.9% vs. 21%). Hot flashes were more predictive of outcome for tamoxifen-treated patients than age, hormone-receptor status, or stage of the primary tumor when evaluating comparison stage I to II B, Dr. Mortimer stated.

During the same meeting at the annual meeting of the American Society of Clinical Oncology, women who have developed recurrent disease or second primary tumors, said Dr. Mortimer, professor of clinical medicine and deputy director of clinical oncology at the Moores Cancer Center, Johns Hopkins University, Baltimore.}

ONCOLOGY

Cardiovascular Pathology

Adverse Event n % n %

Women with hot flashes had significantly fewer breast cancer-specific events than women without hot flashes (12.9% vs. 21%). Hot flashes were more predictive of outcome for tamoxifen-treated patients than age, hormone-receptor status, or stage of the primary tumor when evaluating comparison stage I to II B, Dr. Mortimer stated.

During the same meeting at the annual meeting of the American Society of Clinical Oncology, women who have developed recurrent disease or second primary tumors, said Dr. Mortimer, professor of clinical medicine and deputy director of clinical oncology at the Moores Cancer Center, Johns Hopkins University, Baltimore.}